Hardware Podcasts

044 -“Market Access” with Kasem Akhras

Let's Combinate · 3 Aug 2022 · 1h 13m

What this episode covers

Dr. Kasem Akhras, Senior Director at Novartis and author of 'Frontiers in Market Access', explains the evolution of market access from the 1980s to the present, detailing how managed care organizations shifted power from physicians to payers. He defines 'translational access' as the integration of health economics and outcomes research (HEOR) into early clinical development to shape Target Product Profiles (TPP) and secure reimbursement. Akhras discusses value-based pricing models, including cost-per-quality-adjusted-life-year (QALY) metrics, and explains why US pharmaceutical prices are higher due to statutory discounts and a fragmented, for-profit system compared to international reference pricing.

Most relevant to

large enterprises

Topics

Mentioned

Companies
Novartis, Geneconomics & Outcomes Research, AstraZeneca, Pfizer, Takeda, J&J, Sanofi
Also
Frontiers in Market Access, FDA, EMA, NICE

Related episodes from other shows

Other shows on the same ground, closest first.

  • Global Medical Device Podcast · 37m

    #403: Global Perspective on Medical Device Reimbursement

    Etienne Nichols interviews Karandeep Singh Badwal, a regulatory and reimbursement expert, about integrating reimbursement strategy into medical device development across the US, EU, and Asian markets. They discuss specific systems like US Medicare and CPT codes, EU fragmentation with national programs like Germany's NUB, and Asian pricing models, emphasizing that reimbursement must be a core business strategy from day one. Badwal highlights the importance of hiring jurisdiction-specific experts, leveraging post-market surveillance for real-world evidence, and using management reviews to align quality and business goals. The conversation concludes with a comparison of US and EU reimbursement pros and cons, stressing the need for strategic flexibility in a changing political landscape.

    Pricing, margins & unit economicsCertification & compliance
    13 chapters

  • Global Medical Device Podcast · 39m

    #465: Why Good Medical Devices Fail: Reimbursement Strategy with Ali Samiian

    Ali Samiian, founder of Popular Access Advisors, explains why medical device companies fail commercially by treating reimbursement as a post-FDA paperwork exercise rather than a core product strategy. He details how product design, clinical trial endpoints, and regulatory pathways (such as 510(k) vs. De Novo) must align with payer requirements for durable medical equipment (DME) or other categories to ensure coverage. Samiian highlights the importance of demonstrating durability, standard-of-care comparisons, and value to the healthcare system to secure appropriate pricing from CMS and private payers.

    Validation & product-market fitPricing, margins & unit economics
    9 chapters

  • How I Built This · 34m

    HIBT Lab! Mark Cuban Cost Plus Drug Company: Mark Cuban

    Serial entrepreneur Mark Cuban discusses his newest venture, the Mark Cuban Cost Plus Drug Company (MCCPDC), which he co-founded with radiologist Alex Oshmiansky to disrupt the pharmaceutical industry by offering generic drugs at transparent, low costs. Cuban explains how he educated himself on the complex drug pricing ecosystem, identifying Pharmacy Benefit Managers (PBMs) and vertically integrated insurance companies as the primary drivers of inflated prices rather than manufacturing costs. He details the company's business model as a public benefit corporation that charges a flat 15% markup plus handling and shipping fees, bypassing traditional insurance rebates to undercut standard co-pays. Cuban also touches on his interest in NFTs, his strategy for staying grounded through social media feedback, and his belief that wealthy individuals have a responsibility to fund solutions for systemic problems like high drug prices.

    Pricing, margins & unit economicsStarting a product company
    6 chapters

The summary, chapters and topics are generated from the episode’s audio by this directory, not written by Let's Combinate. The episode itself belongs to its publisher.